Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2021-09-09 , DOI: 10.1111/apt.16601
Thomas A Wichelmann ₁ , Sufyan Abdulmujeeb ₁ , Eli D Ehrenpreis ₁

Affiliation

Bevacizumab is used in the treatment of advanced malignancies and has a “black box” warning for gastrointestinal perforations. Despite this known side effect, there are no large descriptive series of patients who experience bevacizumab-induced gastrointestinal perforations.

中文翻译：